Astonea Labs

Which are the latest news on Astonea Labs?

Why is Astonea Labs Ltd falling/rising?

As of 05-Sep, Astonea Labs Ltd's stock price is currently at 268.00, reflecting a decline and underperformance in its sector. Despite a strong year-to-date gain of 63.91%, recent trading patterns and decreased investor participation indicate short-term struggles and downward pressure.

As of 05-Sep, Astonea Labs Ltd's stock price is falling, currently at 268.00, which reflects a decrease of 2.0 (-0.74%). The stock has underperformed its sector by 0.29% today and opened with a significant loss of 3.7%. Throughout the day, it reached an intraday low of Rs 257, marking a decline of 4.81%. <BR><BR>Additionally, the stock has shown erratic trading patterns, not trading on 3 out of the last 20 days, which may contribute to investor uncertainty. There has also been a notable decrease in investor participation, with delivery volume dropping by 37.5% compared to the 5-day average. <BR><BR>While the stock has performed well year-to-date with a gain of 63.91%, the recent trends indicate a struggle, particularly in the short term, as it is currently trading below its 5-day and 20-day moving averages, despite being above the 50-day, 100-day, and 200-day moving averages. This combination of factors suggests that the stock is facing downward pressure in the current market environment.

What does Astonea Labs do?

Astonea Labs Ltd is a Micro Cap company in the Pharmaceuticals & Biotechnology industry, incorporated in 2017 and previously known as AHU Laboratories. It has a market cap of INR 289 Cr, with no recent revenue or profit data available.

Overview: <BR>Astonea Labs Ltd is a company operating in the Pharmaceuticals & Biotechnology industry within the Micro Cap market-cap bracket.<BR><BR>History: <BR>Astonea Labs Limited was originally incorporated as "AHU Laboratories Private Limited" in 2017. The company changed its name to "Astonea Labs Private Limited" on February 26, 2019, and subsequently to "Astonea Labs Limited" on January 11, 2024. Revenue and profit data are not available for the latest quarter.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 289 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 64.00 <BR>Industry P/E: N/A <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.75 <BR>Return on Equity: 7.91% <BR>Price-to-Book: 5.05<BR><BR>Contact Details: <BR>Address: Not available <BR>Phone: Not available <BR>Email: Not available <BR>Website: Not available

Who are the peers of the Astonea Labs?

Astonea Labs' peers include Medicamen Biotec, Trident Lifeline, Gennex Lab., BDH Industries, Zenotech Lab., Everest Organics, Aarey Drugs, Lyka Labs, and Nectar Lifesci. Astonea Labs has a 1-year return of 57.61%, outperforming BDH Industries (54.17%) and Kerala Ayurveda (-63.87%).

Peers: The peers of Astonea Labs are Medicamen Biotec, Trident Lifeline, Gennex Lab., BDH Industries, Zenotech Lab., Everest Organics, Aarey Drugs, Lyka Labs, and Nectar Lifesci.<BR><BR>Quality Snapshot: Excellent management risk is observed at BDH Industries, while Average management risk is found at Medicamen Biotec, Trident Lifeline, Gennex Lab., Zenotech Lab., Astonea Labs, Everest Organics, Lyka Labs, and Nectar Lifesci, and the rest. Below Average management risk is noted at Aarey Drugs and Kerala Ayurveda. Growth is Excellent at Trident Lifeline, Good at Astonea Labs, Average at Gennex Lab. and the rest, and Below Average at Medicamen Biotec, BDH Industries, Zenotech Lab., Everest Organics, Aarey Drugs, Lyka Labs, Nectar Lifesci, and Kerala Ayurveda. Capital Structure is Excellent at Gennex Lab. and BDH Industries, Good at Medicamen Biotec, and Below Average at Astonea Labs, Everest Organics, Aarey Drugs, Lyka Labs, Nectar Lifesci, and Kerala Ayurveda.<BR><BR>Return Snapshot: The peer with the highest 1-year return is BDH Industries at 54.17%, while the peer with the lowest is Kerala Ayurveda at -63.87%. Astonea Labs has a 1-year return of 57.61%, which is higher than both of these peers. Additionally, peers with a negative six-month return include Everest Organics and Kerala Ayurveda.

How big is Astonea Labs?

As of 13th August, Astonea Labs Ltd has a market capitalization of 287.00 Cr, classifying it as a Micro Cap company, with Shareholder's Funds of 57.13 Cr and Total Assets of 145.71 Cr reported as of March 2026. There is no valid financial data available for net sales or net profit for the latest four quarters.

As of 13th August, <BR><BR>Market Cap: Astonea Labs Ltd has a market capitalization of 287.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for net sales or net profit for the latest four quarters.<BR><BR>Balance Sheet Snapshot: The latest reporting period is March 2026, with Shareholder's Funds amounting to 57.13 Cr and Total Assets totaling 145.71 Cr.

When is the next results date for Astonea Labs Ltd?

The next results date for Astonea Labs Ltd is 30 May 2026.

The next results date for Astonea Labs Ltd is scheduled for 30 May 2026.

Is Astonea Labs overvalued or undervalued?

As of August 28, 2025, Astonea Labs is considered very expensive with a PE ratio of 34.32, significantly higher than its peers, indicating overvaluation and underperformance, as it has declined 3.48% recently compared to a 2.34% drop in the Sensex.

As of 28 August 2025, Astonea Labs' valuation grade has moved from fair to very expensive, indicating a significant shift in its market perception. The company is currently overvalued, with a PE ratio of 34.32, a Price to Book Value of 15.34, and an EV to EBITDA of 14.93. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Astonea Labs' PE ratio is higher than Sun Pharma's 33.18 and significantly above Cipla's attractive PE of 23.65. The PEG ratio of Astonea Labs stands at 0.00, which is unusual and raises concerns about future growth expectations. Recent stock performance shows a decline of 3.48% over the past week, while the Sensex fell only 2.34%, reinforcing the notion that Astonea Labs is not only overvalued but also underperforming relative to the broader market.

How has been the historical performance of Astonea Labs?

Astonea Labs has shown gradual profitability improvement over the past three years, with a profit before tax rising from 0.00 Cr in March 2022 to 5.00 Cr in March 2024. Cash flow from operating activities turned positive at 4.00 Cr in March 2024, while cash flow from investing activities remained negative.

Answer:<BR>The historical performance of Astonea Labs shows a gradual improvement in profitability over the past three years, despite the absence of standalone annual results and balance sheet data.<BR><BR>Breakdown:<BR>In the cash flow results, Astonea Labs reported a profit before tax of 5.00 Cr in March 2024, a significant increase from 1.00 Cr in March 2023 and up from 0.00 Cr in March 2022. Adjustments remained stable at 6.00 Cr for both March 2024 and March 2023, while it was slightly lower at 5.00 Cr in March 2022. Changes in working capital showed a decrease in negative values, with -7.00 Cr in both March 2024 and March 2023, compared to -10.00 Cr in March 2022. Consequently, cash flow after changes in working capital improved to 4.00 Cr in March 2024, up from 0.00 Cr in March 2023 and a negative 4.00 Cr in March 2022. Cash flow from operating activities also turned positive at 4.00 Cr in March 2024, contrasting with -1.00 Cr in March 2023 and -4.00 Cr in March 2022. However, cash flow from investing activities was negative, amounting to -7.00 Cr in March 2024, compared to -3.00 Cr in the previous two years. Cash flow from financing activities decreased to 3.00 Cr in March 2024 from 4.00 Cr in March 2023 and 8.00 Cr in March 2022. Overall, the net cash inflow/outflow remained at 0.00 Cr for all three years, indicating no change in cash position.

Who are the top shareholders of the Astonea Labs?

Astonea Labs is primarily owned by its promoters, who hold the majority of shares with no pledged holdings. There are no mutual funds, foreign institutional investors, or notable individual public shareholders involved.

Astonea Labs is primarily owned by its promoters, who hold the majority of the shares. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. Additionally, there are no notable individual investors or public shareholders listed. This indicates a concentrated ownership structure primarily focused within the promoter group.

Has Astonea Labs declared dividend?

No Dividend History Available